

# Chimeric HLA-A\*02:01 ( $\alpha 3$ ) & mB2M&MAGE-A2 (KMVELVHFL) Monomer Protein



Cat. No. MHC-HM104

## Description

<b>Source</b>	Recombinant Chimeric HLA-A*02:01 ( $\alpha 3$ ) & mB2M&MAGE-A2 (KMVELVHFL) Monomer Protein is expressed from HEK293 with His tag at the C-terminus.
	It contains Gly25-Thr206 (Human HLA-A*02:01 $\alpha 1$ & $\alpha 2$ ) and Asp207-Glu299 (Mouse H-2Ld $\alpha 3$ ), Ile21-Met119 (mB2M) and KMVELVHFL peptide.
<b>Accession</b>	A0A140T913(Human HLA-A*02:01 $\alpha 1$ & $\alpha 2$ )&P01897(Mouse H-2Ld $\alpha 3$ )&&P01887(Mouse B2M)&KMVELVHFL
<b>Molecular Weight</b>	The protein has a predicted MW of 48.00 kDa. Due to glycosylation, the protein migrates to 50-65 kDa based on Tris-Bis PAGE result.
<b>Endotoxin</b>	Less than 1EU per $\mu$ g by the LAL method.
<b>Purity</b>	> 95% as determined by Tris-Bis PAGE > 95% as determined by HPLC

## Formulation and Storage


<b>Formulation</b>	Supplied as 0.22 $\mu$ m filtered solution in PBS (pH 7.4).
<b>Storage</b>	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

## Background

Melanoma antigen gene (MAGE)-A2 (MAGEA2) is a member of the MAGE-A family proteins widely studied for cancer vaccine development and identification of tumor markers. MAGEA2 plays an oncogenic role in glioma progression, and they provide insight into MAGEA2 application as a novel predictor of clinical outcomes and a potential glioma biomarker.


## Assay Data

### Tris-Bis PAGE



Chimeric HLA-A\*02:01 ( $\alpha 3$ ) & mB2M&MAGE-A2 (KMVELVHFL) Monomer on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

### SEC-HPLC



The purity of Chimeric HLA-A\*02:01 ( $\alpha 3$ ) & mB2M&MAGE-A2 (KMVELVHFL) Monomer is greater than 95% as determined by SEC-HPLC.